{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:24:31Z","timestamp":1792661071864,"version":"4.5.0"},"reference-count":68,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNS"],"published-print":{"date-parts":[[2008,10]]},"abstract":"<jats:sec>\n<jats:title>Object<\/jats:title>\n<jats:p>Cyclosporine neuroprotection has been reported in brain injury models but safety and dosing guidelines have not been determined in humans with severe traumatic brain injury (TBI). The purpose of this investigation was to establish the safety of cyclosporine using 4 clinically relevant dosing schemes.<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The authors performed a prospective, blinded, placebo-controlled, randomized, dose-escalation trial of cyclosporine administration initiated within 8 hours of TBI (Glasgow Coma Scale score range 4\u20138; motor score range 2\u20135). Four dosing cohorts (8 patients treated with cyclosporine and 2 receiving placebo treatment per cohort) received cyclosporine (1.25\u20135 mg\/kg\/day) or placebo in 2 divided doses (Cohorts I\u2013III) or continuous infusion (Cohort IV) over 72 hours. Adverse events and outcome were monitored for 6 months.<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Forty patients were enrolled over 3 years (cyclosporine cohorts, 24 male and 8 female patients; placebo group, 8 male patients). Systemic trough concentrations were below 250 ng\/ml during intermittent doses. Higher blood concentrations were observed in Cohorts III and IV. There was no significant difference in immunological effects, adverse events, infection, renal dysfunction, or seizures. Mortality rate was not affected by cyclosporine administration, independent of dose, compared with placebo (6 of 32 patients receiving cyclosporine and 2 of 8 receiving placebo died, p &gt; 0.05). At 6 months, a dose-related improvement in favorable outcome was observed in cyclosporine-treated patients (p &lt; 0.05).<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In patients with acute TBI who received cyclosporine at doses up to 5 mg\/kg\/day, administered intravenously, with treatment initiated within 8 hours of injury, the rate of mortality or other adverse events was not significantly different from that of the placebo group.<\/jats:p><\/jats:sec>","DOI":"10.3171\/jns\/2008\/109\/10\/0699","type":"journal-article","created":{"date-parts":[[2008,9,30]],"date-time":"2008-09-30T18:01:14Z","timestamp":1222797674000},"page":"699-707","source":"Crossref","is-referenced-by-count":95,"title":["Dosing and safety of cyclosporine in patients with severe brain injury"],"prefix":"10.3171","volume":"109","author":[{"given":"Jimmi","family":"Hatton","sequence":"first","affiliation":[{"name":"The Spinal Cord and Brain Injury Research Center;"},{"name":"Departments of Pharmacy Practice and Science, and"},{"name":"Department of Neurosurgery, College of Medicine; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Rosbolt","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, College of Medicine; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Empey","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences, College of Pharmacy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kryscio","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, College of Public Heath, University of Kentucky, Lexington, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron","family":"Young","sequence":"additional","affiliation":[{"name":"The Spinal Cord and Brain Injury Research Center;"},{"name":"Department of Neurosurgery, College of Medicine; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"key":"b1-1090699","series-title":"Exp Neurol","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1006\/exnr.1999.7338","article-title":"Cyclosporin ameliorates traumatic brain-injury induced alterations of hippocampal synaptic plasticity","volume":"162","author":"Albensi","year":"2000"},{"key":"b2-1090699","series-title":"J Neurotrauma","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1089\/08977150260190429","article-title":"Cyclosporin A improves brain tissue oxygen consumption and learning\/memory performance after lateral fluid percussion injury in rats","volume":"19","author":"Alessandri","year":"2002"},{"key":"b3-1090699","series-title":"Curr Top Med Chem","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.2174\/1568026033451871","article-title":"Immunophilins in nervous system degeneration and regeneration","volume":"3","author":"Avramut","year":"2003"},{"key":"b4-1090699","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3171\/jns.1996.85.3.0476","article-title":"Blood-brain barrier breach following cortical contusion in the rat","volume":"85","author":"Baldwin","year":"1996"},{"key":"b5-1090699","series-title":"J Head Trauma Rehabil","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/00001199-200505000-00002","article-title":"The public health approach to traumatic brain injury: an overview of CDC's research and programs","volume":"20","author":"Binder","year":"2005"},{"key":"b6-1090699","series-title":"Brain Res","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0006-8993(02)03474-1","article-title":"Bradykinin receptor agonist facilitates low-dose cyclosporin-A protection against 6-hydroxydopamine neurotoxicity","volume":"956","author":"Borlongan","year":"2002"},{"issue":"Suppl","key":"b7-1090699","series-title":"J Neurotrauma","first-page":"S1","article-title":"Guidelines for the management of severe traumatic brain injury","volume":"24","year":"2007"},{"key":"b8-1090699","series-title":"J Neurotrauma","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1089\/neu.1999.16.511","article-title":"Postinjury cyclosporin A administration limits axonal damage and disconnection in traumatic brain injury","volume":"16","author":"B\u00fcki","year":"1999"},{"key":"b9-1090699","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/00006123-199908000-00001","article-title":"Current status of neuroprotection trials for traumatic brain injury: lessons from animal models and clinical studies","volume":"45","author":"Bullock","year":"1999"},{"key":"b10-1090699","series-title":"Exp Neurol","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.expneurol.2007.01.023","article-title":"Temporal relationship of peroxynitrite-induced oxidative damage, calpain-mediated cytoskeletal degradation and neurodegeneration after traumatic brain injury","volume":"205","author":"Deng","year":"2007"},{"key":"b11-1090699","series-title":"Brain Res Mol Brain Res","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.molbrainres.2003.11.006","article-title":"Neuroprotection by cyclosporin A following transient brain ischemia correlates with the inhibition of the early efflux of cytochrome C to cytoplasm","volume":"121","author":"Doma\u00f1ska-Janik","year":"2004"},{"key":"b12-1090699","series-title":"J Neurotrauma","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/neu.2006.23.109","article-title":"Cyclosporin A disposition following acute traumatic brain injury","volume":"23","author":"Empey","year":"2006"},{"key":"b13-1090699","series-title":"Acta Neurochir (Wien)","first-page":"101","article-title":"Lessons from epidemiologic studies in clinical trials of traumatic brain injury","volume":"89","author":"Farin","year":"2004"},{"key":"b14-1090699","series-title":"Exp Brain Res","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/PL00005622","article-title":"Changes in the bioenergetic state of rat hippocampus during 2.5 min of ischemia, and prevention of cell damage by cyclosporin A in hyperglycemic subjects","volume":"114","author":"Folbergrova","year":"1997"},{"key":"b15-1090699","series-title":"J Neurosurg Anesthesiol","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/00008506-199804000-00006","article-title":"A case of severe cerebral trauma in a patient under chronic treatment with cyclosporine A","volume":"10","author":"Gogarten","year":"1998"},{"key":"b16-1090699","series-title":"J Neurotrauma","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1089\/089771504772695904","article-title":"Peroxynitrite-mediated protein nitration and lipid peroxidation in a mouse model of traumatic brain injury","volume":"21","author":"Hall","year":"2004"},{"key":"b17-1090699","series-title":"CNS Drugs","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2165\/00023210-200115070-00005","article-title":"Pharmacological treatment of traumatic brain injury: a review of agents in development","volume":"15","author":"Hatton","year":"2001"},{"key":"b18-1090699","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3171\/jns.2006.105.6.843","article-title":"Systemic metabolic effects of combined insulin-like growth factor-I and growth hormone therapy in patients who have sustained acute traumatic brain injury","volume":"105","author":"Hatton","year":"2006"},{"key":"b19-1090699","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3171\/jns.1997.86.5.0779","article-title":"Intravenous insulin-like growth factor I (IGF-I) in moderate to severe head injury: a phase II safety and efficacy trial","volume":"86","author":"Hatton","year":"1997"},{"key":"b20-1090699","series-title":"Biol Pharm Bull","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1248\/bpb.26.1115","article-title":"Relationship between development of nephrotoxicity and blood concentration of cyclosporine A in bonemarrow transplanted recipients who received the continuous intravenous infusion","volume":"26","author":"Kagawa","year":"2003"},{"key":"b21-1090699","series-title":"J Neurotrauma","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1089\/089771503322686139","article-title":"Differential effects of traumatic brain injury on the cytochrome p450 system: a perspective into hepatic and renal drug metabolism","volume":"20","author":"Kalsotra","year":"2003"},{"key":"b22-1090699","series-title":"J Cell Mol Med","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1582-4934.2004.tb00259.x","article-title":"Molecular mechanisms of neuroprotective action of immunosuppressants\u2013 facts and hypotheses","volume":"8","author":"Kaminska","year":"2004"},{"key":"b23-1090699","series-title":"J Bioenerg Biomembr","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1023\/B:JOBB.0000041759.35731.70","article-title":"The mitochondrial permeability transition as a target for neuroprotection","volume":"36","author":"Kristal","year":"2004"},{"key":"b24-1090699","series-title":"Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations, and Deaths","author":"Langlois","year":"2006"},{"key":"b25-1090699","series-title":"Mol Neurobiol","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1385\/MN:24:1-3:169","article-title":"The duality of the inflammatory response to traumatic brain injury","volume":"24","author":"Lenzlinger","year":"2001"},{"key":"b26-1090699","series-title":"Restor Neurol Neurosci","first-page":"73","article-title":"Inhibition of vascular endothelial growth factor receptor (VEGFR) signalizing by BSF476921 attenuates regional cerebral edema following traumatic brain injury in rats","volume":"22","author":"Lenzlinger","year":"2004"},{"key":"b27-1090699","series-title":"J Neurotrauma","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1089\/neu.2000.17.871","article-title":"Free radical pathways in CNS injury","volume":"17","author":"Lew\u00e9n","year":"2000"},{"key":"b28-1090699","series-title":"Brain Res","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0006-8993(97)00005-X","article-title":"Amelioration by cyclosporin A of brain damage following 5 to 10 min of ischemia in rats subjected to preischemic hyperglycemia","volume":"753","author":"Li","year":"1997"},{"key":"b29-1090699","series-title":"Mitochondrion","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.mito.2004.07.021","article-title":"Mitochondrial damage and dysfunction in traumatic brain injury","volume":"4","author":"Lifshitz","year":"2004"},{"issue":"Suppl 89","key":"b30-1090699","series-title":"Acta Neurochir","first-page":"113","article-title":"Clinical trials in traumatic brain injury: current problems and future solution","author":"Maas","year":"2004"},{"key":"b31-1090699","series-title":"Lancet Neurol","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(05)70253-2","article-title":"Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial","volume":"5","author":"Maas","year":"2006"},{"key":"b32-1090699","series-title":"Neurosurgery","first-page":"1286","article-title":"Why have recent trials of neuroprotective agents in head injury failed to show convincing efficacy? A pragmatic analysis and theoretical considerations","volume":"44","author":"Maas","year":"1999"},{"key":"b33-1090699","series-title":"J Neurochem","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1046\/j.1471-4159.2003.01772.x","article-title":"Brain edema induced by in vitro ischemia: causal factors and neuroprotection","volume":"85","author":"MacGregor","year":"2003"},{"key":"b34-1090699","series-title":"J Neurotrauma","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1089\/neu.1999.16.1131","article-title":"Evaluation of designs for clinical trials of neuroprotective agents in head injury","volume":"16","author":"Machado","year":"1999"},{"key":"b35-1090699","series-title":"Restor Neurol Neurosci","first-page":"105","article-title":"The assessment of genomic alterations using DNA arrays following traumatic brain injury: a review","volume":"18","author":"Marciano","year":"2001"},{"key":"b36-1090699","series-title":"Neurochem Res","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1023\/A:1020973308941","article-title":"Expression profiling following traumatic brain injury: a review","volume":"27","author":"Marciano","year":"2002"},{"key":"b37-1090699","series-title":"Curr Pharm Des","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.2174\/138161206776843340","article-title":"Evaluation of pharmacological treatment strategies in traumatic brain injury","volume":"12","author":"Marklund","year":"2006"},{"key":"b38-1090699","series-title":"J Neurotrauma","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1089\/neu.2005.22.1444","article-title":"A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury","volume":"22","author":"Marmarou","year":"2005"},{"key":"b39-1090699","series-title":"Central Nervous System Injury Surveillance: Annual Data Submission Standards for the Year 2002","author":"Marr","year":"2001"},{"issue":"Suppl","key":"b40-1090699","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.3171\/sup.1991.75.1s.0s14","article-title":"A new classification of head injury based on computerized tomography","volume":"75","author":"Marshall","year":"1991"},{"key":"b41-1090699","series-title":"Neuroscience","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuroscience.2005.08.030","article-title":"Neuroscience experimental models of traumatic brain injury: do we really need to build a better mousetrap?","volume":"136","author":"Morales","year":"2005"},{"key":"b42-1090699","series-title":"J Neurotrauma","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1089\/089771502753754037","article-title":"Clinical trials in head injury","volume":"19","author":"Narayan","year":"2002"},{"key":"b43-1090699","series-title":"Neuroreport","first-page":"463","article-title":"Dose-response of cyclosporin A in attenuating traumatic axonal injury in rat","volume":"14","author":"Okonkwo","year":"2003"},{"key":"b44-1090699","series-title":"J Cereb Blood Flow Metab","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/00004647-199904000-00010","article-title":"An intrathecal bolus of cyclosporine A before injury preserves mitochondrial integrity and attenuates axonal disruption in traumatic brain injury","volume":"19","author":"Okonkwo","year":"1999"},{"key":"b45-1090699","series-title":"J Neurochem","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1046\/j.0022-3042.2002.00777.x","article-title":"Local and systemic increase in lipid peroxidation after moderate experimental traumatic brain injury","volume":"80","author":"Pratico","year":"2002"},{"key":"b46-1090699","series-title":"J Head Trauma Rehabil","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/00001199-200501000-00008","article-title":"Update of neuropathology and neurological recovery after traumatic brain injury","volume":"20","author":"Povlishock","year":"2005"},{"key":"b47-1090699","series-title":"J Neurotrauma","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1089\/neu.2000.17.927","article-title":"Apoptosis after traumatic brain injury","volume":"17","author":"Raghupathi","year":"2000"},{"key":"b48-1090699","series-title":"Restor Neurol Neurosci","first-page":"1","article-title":"Effects of chronic, post-injury cyclosporin A administration on motor and sensorimotor function following severe, experimental traumatic brain injury","volume":"18","author":"Riess","year":"2001"},{"key":"b49-1090699","series-title":"Curr Opin Pharmacol","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1471-4892(02)00006-1","article-title":"Pharmacology of traumatic brain injury","volume":"3","author":"Royo","year":"2003"},{"key":"b50-1090699","series-title":"Curr Pharm Des","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.2174\/1381612013397311","article-title":"Current aspects of pathophysiology and cell dysfunction after severe head injury","volume":"7","author":"Sahuquillo","year":"2001"},{"key":"b51-1090699","series-title":"J Neurotrauma","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1089\/neu.1999.16.783","article-title":"Cyclosporin A significantly ameliorates cortical damage following experimental traumatic brain injury in rodents","volume":"16","author":"Scheff","year":"1999"},{"key":"b52-1090699","series-title":"Brain Res","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0006-8993(92)91465-Q","article-title":"Cyclosporin A protects against ischemia-reperfusion injury in the brain","volume":"595","author":"Shiga","year":"1992"},{"key":"b53-1090699","series-title":"J Neurotrauma","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1089\/neu.2004.21.1154","article-title":"The protective effect of cyclosporin A upon N-acetylaspartate and mitochondrial dysfunction following experimental diffuse traumatic brain injury","volume":"21","author":"Signoretti","year":"2004"},{"key":"b54-1090699","series-title":"Neurobiol Dis","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.nbd.2004.03.016","article-title":"Proteins released from degenerating neurons are surrogate markers for acute brain damage","volume":"16","author":"Siman","year":"2004"},{"key":"b55-1090699","series-title":"J Cereb Blood Flow Metab","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/sj.jcbfm.9600297","article-title":"Time course of post-traumatic mitochondrial oxidative damage and dysfunction in a mouse model of focal traumatic brain injury: implications for neuroprotective therapy","volume":"26","author":"Singh","year":"2006"},{"key":"b56-1090699","series-title":"Brain Res","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S0006-8993(02)02968-2","article-title":"Cytochrome C release and caspase activation after traumatic brain injury","volume":"949","author":"Sullivan","year":"2002"},{"key":"b57-1090699","series-title":"Neuroscience","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0306-4522(00)00380-8","article-title":"Dose-response curve and optimal dosing regimen of cyclosporine A after traumatic brain injury in rats","volume":"101","author":"Sullivan","year":"2000"},{"key":"b58-1090699","series-title":"J Neurosci Res","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/jnr.20292","article-title":"Mitochondrial permeability transitions in CNS trauma: cause or effect of neuronal cell death?","volume":"79","author":"Sullivan","year":"2005"},{"key":"b59-1090699","series-title":"J Bioenerg Biomembr","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1023\/B:JOBB.0000041767.30992.19","article-title":"Mitochondrial uncoupling as a therapeutic target following neuronal injury","volume":"36","author":"Sullivan","year":"2004"},{"key":"b60-1090699","series-title":"Exp Neurol","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1006\/exnr.1999.7282","article-title":"Continuous infusion of cyclosporin A postinjury significantly ameliorates cortical damage following traumatic brain injury","volume":"161","author":"Sullivan","year":"2000"},{"key":"b61-1090699","series-title":"Exp Neurol","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1006\/exnr.1999.7197","article-title":"Cyclosporin A attenuates acute mitochondrial dysfunction following traumatic brain injury","volume":"160","author":"Sullivan","year":"1999"},{"key":"b62-1090699","series-title":"Exp Neurol","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.expneurol.2006.04.013","article-title":"Relationship of calpain-mediated proteolysis to the expression of axonal and synaptic plasticity markers following traumatic brain injury in mice","volume":"201","author":"Thompson","year":"2006"},{"key":"b63-1090699","series-title":"Traumatic Brain Injury in the United States: A Report to Congress. December 1999","author":"Thurman","year":"1999"},{"key":"b64-1090699","series-title":"Drug Metab Dispos","first-page":"1064","article-title":"Head injury and cytochrome P-450 enzymes. Differential effect on mRNA and protein expression in the Fischer-344 rat","volume":"21","author":"Toler","year":"1993"},{"issue":"Suppl 86","key":"b65-1090699","series-title":"Acta Neurochir","first-page":"105","article-title":"Calcineurin and cyclophilin D are differential targets of neuroprotection by immunosuppressants CsA and FK506 in ischemic brain damage","author":"Uchino","year":"2003"},{"key":"b66-1090699","series-title":"Neurobiol Dis","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1006\/nbdi.2002.0514","article-title":"Differential neuroprotection by cyclosporin A and FK506 following ischemia corresponds with differing abilities to inhibit calcineurin and the mitochondrial permeability transition","volume":"10","author":"Uchino","year":"2002"},{"key":"b67-1090699","series-title":"J Neurotrauma","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1089\/neu.2004.21.1562","article-title":"Downregulation of amyloid precursor protein (APP) expression following post-traumatic cyclosporine-A administration","volume":"21","author":"Van Den Heuvel","year":"2004"},{"issue":"Suppl","key":"b68-1090699","series-title":"Acta Pol Pharm","first-page":"129","article-title":"In vivo brain microdialysis as a tool in studies of neuroprotective effects of cyclosporin A in acute excitotoxicity","volume":"57","author":"Zieminska","year":"2000"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/109\/4\/article-p699.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/109\/4\/article-p699.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/109\/4\/article-p699.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T07:34:22Z","timestamp":1664177662000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/109\/4\/article-p699.xml"}},"subtitle":["Clinical article"],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":68,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3171\/jns\/2008\/109\/10\/0699","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}